HTB homepage • Conference reports • Articles by subject • Subscribe July 2019 Contents Editorial HTB 24 July 2019 online: first reports from IAS 2019 HTB 17 July 2019 online: IAS 2019, HIV pipeline, gene-cure mice… Special reports Fit for purpose 2019 – PDF HIV pipeline report 2019 Conference reports 10th IAS Conference on HIV Science (IAS 2019) in Mexico City Dolutegravir neural tube defect risk declines but still slightly higher than with other antiretrovirals WHO recommends dolutegravir-based ART regimens for all High rates of viral suppression with low dose efavirenz in pregnant Zambian women First viral load results for capsid inhibitor GS-6207: mean –2.2 log reduction at day 10 Islatravir (MK-8591) with doravirine plus lamivudine: 24 week results Dual therapy with islatravir (MK-8591) plus doravirine: 24 week results as switch strategy Fostemsavir: 96-week follow-up in people with multi-drug resistance Dolutegravir/lamivudine dual therapy non-inferior to triple ART at week-96 Switching to dolutegravir/lamivudine dual therapy is non-inferior to TAF-based triple therapy at week-48 in TANGO study Islatravir (MK-8591) implant sustains HIV PrEP protection for more than one year Upcoming 10th IAS Conference on HIV Science (IAS 2019) IAS 2019: late breaker highlights to look for Antiretrovirals Dolutegravir/lamivudine approved as dual HIV combination in EU Guidelines IAS–USA update of drug resistance mutations (2019) Cure-related research HIV risk to partners of people in studies with a treatment interruption Gene editing to eliminate HIV from mice: misleading and wrongly reported in media coverage Other news UNAIDS call on 48 countries and territories to remove all HIV-related travel restrictions PDFs 24 July 2019 vol 20 no 9 17 July 2019 vol 20 no 8 HTB homepage • Conference reports • Articles by subject • Subscribe
